-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 20%-40% of Guillain-Barré syndrome (GBS), also known as Guillain-Barré syndrome, patients will not lose the ability to walk independently during the course of the disease, which is called "mild GBS"
Patients who initially have mild GBS may worsen as the disease progresses
Plasma exchange (PE) and intravenous immune globulin (of IVIg) can not be equally effective for the patient to walk independently GBS (severe GBS)
Immunity due to self-limiting disease, a large proportion of patients spontaneously recover, side effects include allergic reactions or thrombotic embolic events, and IVIg expensive
In this way, Christine Verboon and others of the University of Rotterdam used this difference in current treatment practices to compare the clinical process and results of patients with mild GBS who received supportive care or supportive care and IVIg treatment
They selected patients who were able to walk independently at the beginning of the study (mild GBS) from the prospective observational International GBS Outcome Study (IGOS), treated with an IVIg course or supportive care
Of the 188 eligible patients, 148 (79%) received IVIg treatment, and 40 (21%) received supportive care
They found that the IVIg group had a higher degree of disability at baseline
The important significance of this study lies in the discovery: in patients with mild GBS, a course of IVIg did not improve the entire disease process
In patients with mild GBS, one course of IVIg did not improve the entire disease process.
Leave a message here
